Drugs / TYRA-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06160752 | Nov 2023 → Sep 2026 overdue | intrahepatic cholangiocarcinoma | Tyra Biosciences, Inc | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYRA-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06160752 ↗ |
| Action | Inhibit | “tyrosine kinase inhibitor” NCT06160752 ↗ |
| Modality | Small molecule | “a novel, potent fibroblast growth factor receptor (FGFR) 1/2/3 tyrosine kinase inhibitor” NCT06160752 ↗ |
| Route | Oral | “TYRA-200 taken once daily by mouth” NCT06160752 ↗ |
| Target | FGFR2 | “targets tumors that contain activating gene alterations of FGFR2” NCT06160752 ↗ |